Different effect of sodium butyrate on cancer and normal prostate cells

Toxicology in Vitro

Volumn 27, Issue 5, 2013, Pages 1489-1495

  Paskova, Lenka ^a   Smesny Trtkova, Katerina ^a   Fialova, Barbora ^a   Benedikova, Andrea ^a   Langova, Katerina ^a   Kolar, Zdenek ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Acetylation; Androgen receptor; Coregulators; HDAC inhibitor; Prostate cells; Sodium butyrate

Indexed keywords

ANDROGEN RECEPTOR; BUTYRIC ACID; E1A ASSOCIATED P300 PROTEIN; HISTONE H4; PROSTATE SPECIFIC ANTIGEN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR;

ADULT; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ACETYLATION; BUTYRIC ACID; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84876703842     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.03.002     Document Type: Article

References (31)

1. Advani A.S., Gibson S.E., Douglas E., Jin T., Zhao X., Kalaycio M., Copelan E., Sobecks R., Sekeres M., Sungren S., Hsi E.D. Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer 2010, 10:387.
2. Chen X., Wong J.Y.C., Wong P., Radany E.H. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol. Cancer Res. 2011, 9:448-461.
3. Culig Z., Klocker H., Bartsch G., Hobisch A. Androgen receptor in prostate cancer. Endocrinol.-Relat. Cancer 2002, 9:155-170.
4. Debes J.D., Comuzzi B., Schmidt L.J., Dehm S.M., Culig Z., Tindall D.J. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res. 2005, 65:5965-5973.
5. Dotzlaw H., Moehren U., Mink S., Cato A.C.B., Iñiguez Lluhí J.A., Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol. Endocrinol. 2002, 16:661-673.
6. Ducasse M., Brown M.A. Epigenetic aberrations and cancer. Mol. Cancer 2006, 5:1-10.
7. Frigo D.E., McDonnell D.P. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol. Cancer Ther. 2008, 7:659-669.
8. Fu M., Rao M., Wang Ch., Sakamaki T., Wang J., Di Vizio D., Zhang X., Albanese Ch., Balk S., Chang Ch., Fan S., Rosen E., Palvimo J.J., Jänne O.A., Muratoglu S., Avantaggiati M.L., Pestell R.G. Acetylation of the androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol. Cell. Biol. 2003, 23:8563-8575.
9. Gao X., Loggie B.W., Nawaz Z. The roles of sex steroid receptor coregulators in cancer. Mol. Cancer 2002, 1:1-7.
10. Glass Ch.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000, 14:121-141.
11. Gozzini A., Rovida E., Sbarba P.D., Galimbert S., Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res. 2003, 63:8955-8961.
12. Gu J., Zhao X., Spanjaard R.A., Chen T.C., Flanagan J.N., Boosalis M., Perrine S.P., Faller D.V. Histone deacetylase-inhibitors sensitize human prostate cancer cell lines to growth suppression and apoptosis by retinoids. J. Cancer Mol. 2006, 2:25-36.
13. Huang K.-H., Chiou S.-H., Chow K.-C.h., Lin T.-Y., Chang H.-W., Chiang I.-P., Lee M.-C.h. Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology 2010, 57:384-394.
14. Ishizuka M., Kawate H., Takayanagi R., Ohshima H., Tao R.-H., Hagiwara H. A zinc finger protein TZF is a novel corepressor of androgen receptor. Biochem. Biophys. Res. Commun. 2005, 331:1025-1031.
15. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA-Cancer J. Clin. 2011, 61:69-90.
16. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
17. Kim J., Park H., Im J.Y., Choi W.S., Kim H.S. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Res. 2007, 27:3285-3292.
18. Kinoshita M., Nakagawa T., Shimizu A., Katsuoka Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int. J. Urol. 2005, 12:390-397.
19. Kuefer R., Hofer M.D., Altug V., Zorn C., Genze F., Kunzi-Rapp K., Hautmann R.E., Gschwend J.E. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Brit. J. Cancer. 2004, 90:535-541.
20. Liao G., Chen L.-Y., Zhang A., Godavarthy A., Xia F., Ghosh J.-C.h., Li H., Chen J.D. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 2003, 278:5052-5061.
21. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
22. Popov V.M., Wang Ch., Shirley L.A., Rosenberg A., Li S., Nevalainen M., Fu M., Pestell R.G. The functional significance of nuclear receptor acetylation. Steroids 2007, 72:221-230.
23. Rahman M., Miyamoto H., Chang Ch. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin. Cancer Res. 2004, 10:2208-2219.
24. Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines - Part 1. J. Urol. 2005, 173:342-359.
25. Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines - Part 2. J. Urol. 2005, 173:360-372.
26. Taplin M.-E., Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem. 2004, 91:483-490.
27. Trtkova K., Paskova L., Matijescukova N., Strnad M., Kolar Z. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB. Neoplasma 2010, 57:406-414.
28. Trtkova K., Paskova L., Matijescukova N., Kolar Z. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor. Cancer Biomark. 2010, 7:79-90.
29. Yoon H.-G., Wong J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. 2006, 20:1048-1060.
30. Yuan H., Liddle F.J., Mahajan S., Frank D.A. IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. Carcinogenesis 2004, 25:2247-2255.
31. Zhuang Y.-Q., Li J.-Y., Chen Z.-X., Wang X.-Z. Effects of sodium butyrate on proliferation and differentiation of human gastric carcinoma cell line AGS. Chin. J. Cancer Res. 2008, 27:135-139.